Apilimod clinical trials
Also written STA-5326.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses apilimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- STA-5326
- 6
Studies by the year they started
6 studies that test it; most in 2005 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Synta Pharmaceuticals Corp. (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
Studies
Open first, then newest update. How each study uses apilimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable ImmunodeficiencyCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00263237Written as STA-5326
- The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's DiseaseCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00250198Written as STA-5326
- A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue OutcomesCompletedPhase 2Synta Pharmaceuticals Corp.NCT00642629Written as STA 5326 mesylate
- Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseCompletedPhase 2Synta Pharmaceuticals Corp.NCT00138840Written as STA-5326 mesylate
- Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseCompletedPhase 2Synta Pharmaceuticals Corp.NCT00234741Written as STA-5326 mesylate
- STA-5326 in Crohn's Disease PatientsCompletedPhase 1/2Synta Pharmaceuticals Corp.NCT00088062Written as STA-5326
Codes
What other systems call apilimod · ClinicalTrials.gg INT004816
- MeSH (NLM) C504227apilimodOne source NLM
- UNII (FDA) GFW2K84S4LAPILIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q27279086apilimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90808ApilimodOne source FDA
- DrugBank DB05611One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C504227 | apilimod | One source NLM |
| UNII (FDA) | GFW2K84S4L | APILIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27279086 | apilimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90808 | Apilimod | One source FDA |
| DrugBank | DB05611 | — | One source Wikidata |
Also registered as apilimod mesylate (UNII 5G3P5OK11S).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.